Annual ReportHealthcare

Pharmaniaga Berhad

7081.KL · Period ending 2025-12-31 · Filed 2025-12-31 · Updated

In short

Pharmaniaga Berhad (7081.KL) has revenue up 4.5% to MYR 3.9B and net income down 63.2% to MYR 48.5M year on year. Its net margin is 1.2% and gross margin 10.4%, and it trades at 6.3× trailing earnings. Fisclear flags 1 high-severity risk, led by: Current ratio of 0.91x — short-term liabilities exceed current assets, which could create near-term liquidity pressure. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

RM0.78

P/E (TTM)

6.5x

Price ÷ earnings per share

P/B

2.1x

Price ÷ book value

P/S (TTM)

0.2x

Price ÷ revenue per share

Beta

0.79

Moderate market correlation

52-Week Range

RM0.73RM0.78 nowRM1.70

4-engine score — Quality and Peers engines require SEC EDGAR (US stocks only)

Efficiency
44/100
Value
65/100
Cashflow
46/100
Regime
50/100

P/E 6.5× — low multiple.

Based on filing period ending Dec 2025

International FisclearScore uses 4 engines (no EDGAR data). Based on Yahoo Finance & Alpha Vantage reported financials. Not financial advice.

7081.KL vs

🇲🇾 Malaysia Macro Indicators

Full dashboard →

Policy Rate

2.75%→

Moderate

CPI Inflation

1.80%→

Near target · +0.10% MoM

Unemployment

2.90%↓

Tight labour market

GDP Growth

6.00%↑

Strong

USD/MYR

4.08→

Current Account

1.61% GDP↑

Surplus

The Malaysia central bank policy rate stands at 2.75% — a moderately elevated rate environment; CPI inflation is 1.8% year-over-year (inflation near target); unemployment stands at 2.9% (tight labour market); GDP growth is 6.0% year-over-year (strong growth); USD/MYR is at 4.0843.

SWOT Analysis — 7081.KL

Inflationary Boom
Macro lens (Inflationary Boom): Rising costs and tighter margins amplify financial risks in this regime.
✦

Strengths

  • Total Assets: MYR 2.2B (+12.8% YoY) — Total assets grew 13% — the company's resource base expanded.

◈

Weaknesses

  • EPS (Diluted): MYR 0.07 (-75.4% YoY) — Earnings per share fell 75%.

  • Net Income: MYR 48.5M (-63.2% YoY) — Profit fell 63% but remained positive.

  • Gross Profit: MYR 409.2M (-24.3% YoY) — Gross profit declined 24% — costs are growing faster than revenue.

  • Gross margin narrowed by 4.0pp — worth monitoring for further cost pressure.

◎

Opportunities

  • Revenue: MYR 3.9B (+4.5% YoY) — Revenue grew 4% — the company sold more goods or services than the prior year.

⚠

Threats

  • Current ratio of 0.91x — short-term liabilities exceed current assets, which could create near-term liquidity pressure.

  • Net income dropped 63% year-over-year — a significant compression in profitability.

  • Total liabilities represent 80% of total assets — elevated leverage that amplifies both gains and losses.

  • Stock is within 10% of its 52-week low (0.75) — the market may be pricing in significant risk or sector weakness.

Year-over-Year Changes

EPS (Diluted)

MYR 0.07

was MYR 0.27

−75.4%

Earnings per share fell 75%.

Net Income

MYR 48.5M

was MYR 131.8M

−63.2%

Profit fell 63% but remained positive.

Gross Profit

MYR 409.2M

was MYR 540.5M

−24.3%

Gross profit declined 24% — costs are growing faster than revenue.

Total Assets

MYR 2.2B

was MYR 2.0B

+12.8%

Total assets grew 13% — the company's resource base expanded.

Revenue

MYR 3.9B

was MYR 3.8B

+4.5%

Revenue grew 4% — the company sold more goods or services than the prior year.

Risk Flags

1 high · 3 medium · 1 low
  • ⚠ High

    Current ratio of 0.91x — short-term liabilities exceed current assets, which could create near-term liquidity pressure.

  • ◈ Medium

    Net income dropped 63% year-over-year — a significant compression in profitability.

  • ◈ Medium

    Total liabilities represent 80% of total assets — elevated leverage that amplifies both gains and losses.

  • ◈ Medium

    Stock is within 10% of its 52-week low (0.75) — the market may be pricing in significant risk or sector weakness.

  • ○ Low

    Gross margin narrowed by 4.0pp — worth monitoring for further cost pressure.

Technical Signals

Daily closes · 1-year data

Pharmaniaga Berhad: common questions

Is Pharmaniaga Berhad profitable?

Yes. Pharmaniaga Berhad made a net profit of RM49M in its latest fiscal year (fiscal 2025), a net margin of 1.2%.

Is Pharmaniaga Berhad's revenue growing?

Yes. Revenue grew 4.5% year on year, to MYR 3.9B.

What is Pharmaniaga Berhad's P/E ratio?

Pharmaniaga Berhad trades at 6.5× its trailing twelve-month earnings. In other words, the share price is about 6 times the profit per share the company earned over the past year.

Does Pharmaniaga Berhad pay a dividend?

Yes. Pharmaniaga Berhad's forward dividend yield is 2.23%, the expected annual dividend as a share of the current share price.

What are the main risks for Pharmaniaga Berhad?

Fisclear's checks flag 4 medium- or high-severity risks. The most serious: Current ratio of 0.91x — short-term liabilities exceed current assets, which could create near-term liquidity pressure.

Answers are generated from the figures in this report (updated 6 Nov 2026). Information, not investment advice.

Latest News

via Finnhub

Filing History — 7081.KL

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Research Pharmaniaga Berhad

Data sourced from Bursa Malaysia, FRED (Federal Reserve), OECD, BIS, and Yahoo Finance. For informational purposes only. Not financial advice.